Eli Lilly and Company - Product Pipeline Review - 2016

  • ID: 3641085
  • Company Profile
  • 242 pages
  • Global Markets Direct
  • Eli Lilly and Company
1 of 4
Eli Lilly and Company - Product Pipeline Review - 2016

Summary

‘Eli Lilly and Company - Product Pipeline Review - 2016’, provides an overview of the Eli Lilly and Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company
- The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Eli Lilly and Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Eli Lilly and Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Eli Lilly and Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eli Lilly and Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Eli Lilly and Company Snapshot

Eli Lilly and Company Overview

Key Information

Key Facts

Eli Lilly and Company - Research and Development Overview

Key Therapeutic Areas

Eli Lilly and Company - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Eli Lilly and Company - Pipeline Products Glance

Eli Lilly and Company - Late Stage Pipeline Products

Eli Lilly and Company - Clinical Stage Pipeline Products

Eli Lilly and Company - Early Stage Pipeline Products

Eli Lilly and Company - Drug Profiles

baricitinib

duloxetine hydrochloride DR

ixekizumab

necitumumab

olaratumab

ramucirumab

cetuximab

abemaciclib

AMG-5041

insulin peglispro

LY-2951742

odelepran hydrochloride

solanezumab

tadalafil

galunisertib

blosozumab

edivoxetine hydrochloride

emibetuzumab

erteberel

icrucumab

insulin lispro U100

landogrozumab

LY-2510924

LY-2623091

LY-2874455

LY-2928057

LY-2944876

LY-3015014

LY-3016859

LY-3023414

LY-3074828

merestinib

prexasertib

ralimetinib mesylate

LY-2780301

LY-3039478

Biologic 6 for Diabetes

Biologic for Crohn's Disease

Biologic for Diabetic Nephropathy

Biologic for Hypoglycemia

Biologic for Lupus

Biologic for Neutrophilic Dermatosis

Biologic for Renal Anemia

dulaglutide

insulin lispro U200

LY-2599666

LY-2969822

LY-3002813

LY-3009120

LY-3022855

LY-3025876

LY-3041658

LY-3050258

LY-3076226

LY-3079514

LY-3090106

LY-3108743

LY-3114062

LY-3127760

LY-3127804

LY-3143753

LY-3154207

LY-3164530

LY-3185643

LY-3200327

LY-3202626

LY-3337641

LY-900014

Recombinant Protein for Parkinson's Disease

Small Molecule 4 for Diabetes

cercosporamide

CPZEN-45

LLY-2707

LSN-2463359

LSN-2535717

LSN-2814617

LY-2109761

LY-2607540

LY-2811376 + LY-3002813

LY-2857785

LY-344545

Monoclonal Antibody Conjugate 2 for Oncology

Monoclonal Antibody Conjugate 3 for Oncology

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology

ND-09759

Small Molecule to Agonize TR-Beta for Dyslipidemia

Small Molecule to Antagonize mGlu5 for Pain

Drugs for Oncology

IC-87201

Monoclonal Antibodies for Undisclosed Indication

Small Molecule for Type 2 Diabetes

Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation

Small Molecule to Inhibit MPGES-1 for Inflammation and Pain

Eli Lilly and Company - Pipeline Analysis

Eli Lilly and Company - Pipeline Products by Target

Eli Lilly and Company - Pipeline Products by Route of Administration

Eli Lilly and Company - Pipeline Products by Molecule Type

Eli Lilly and Company - Pipeline Products by Mechanism of Action

Eli Lilly and Company - Recent Pipeline Updates

Eli Lilly and Company - Dormant Projects

Eli Lilly and Company - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Eli Lilly and Company - Company Statement

Eli Lilly and Company - Locations and Subsidiaries

Head Office

Other Locations & Subsidiaries

Eli Lilly and Company - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Eli Lilly and Company, Key Information

Eli Lilly and Company, Key Facts

Eli Lilly and Company - Pipeline by Indication, 2016

Eli Lilly and Company - Pipeline by Stage of Development, 2016

Eli Lilly and Company - Monotherapy Products in Pipeline, 2016

Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2016

Eli Lilly and Company - Partnered Products in Pipeline, 2016

Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2016

Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016

Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2016

Eli Lilly and Company - Pre-Registration, 2016

Eli Lilly and Company - Filing rejected/Withdrawn, 2016

Eli Lilly and Company - Phase III, 2016

Eli Lilly and Company - Phase II, 2016

Eli Lilly and Company - Phase I, 2016

Eli Lilly and Company - Preclinical, 2016

Eli Lilly and Company - Discovery, 2016

Eli Lilly and Company - Pipeline by Target, 2016

Eli Lilly and Company - Pipeline by Route of Administration, 2016

Eli Lilly and Company - Pipeline by Molecule Type, 2016

Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2016

Eli Lilly and Company - Recent Pipeline Updates, 2016

Eli Lilly and Company - Dormant Developmental Projects,2016

Eli Lilly and Company - Discontinued Pipeline Products, 2016

Eli Lilly and Company, Subsidiaries

Eli Lilly and Company, Key Manufacturing Facilities

List of Figures

Eli Lilly and Company - Pipeline by Top 10 Indication, 2016

Eli Lilly and Company - Pipeline by Stage of Development, 2016

Eli Lilly and Company - Monotherapy Products in Pipeline, 2016

Eli Lilly and Company - Partnered Products in Pipeline, 2016

Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016

Eli Lilly and Company - Pipeline by Top 10 Target, 2016

Eli Lilly and Company - Pipeline by Route of Administration, 2016

Eli Lilly and Company - Pipeline by Molecule Type, 2016

Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll